BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. Int J Clin Oncol 2020;25:614-21. [PMID: 31838590 DOI: 10.1007/s10147-019-01600-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Coutzac C, Trouilloud I, Artru P, Henriques J, Masson T, Doat S, Bouché O, Coriat R, Saint A, Moulin V, Vernerey D, Gallois C, Fouchardiere CDL, Tougeron D, Taieb J. Sequential treatment with trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer patients: an AGEO prospective “real-world study”. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2021.12.003] [Reference Citation Analysis]
2 Watanabe D, Fujii H, Yamada Y, Matsuhashi N, Makiyama A, Iihara H, Takahashi T, Kiyama S, Kobayashi R, Yoshida K, Suzuki A. Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. Int J Clin Oncol 2021;26:1257-63. [PMID: 33839963 DOI: 10.1007/s10147-021-01910-2] [Reference Citation Analysis]
3 García-Alfonso P, Muñoz A, Jiménez-Castro J, Jiménez-Fonseca P, Pericay C, Longo-Muñoz F, Reyna-Fortes C, Argilés-Martínez G, González-Astorga B, Gómez-Reina MJ, Ruiz-Casado A, Rodríguez-Salas N, López-López R, Carmona-Bayonas A, Conde-Herrero V, Aranda E, On Behalf Of The Ros Study Group. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers (Basel) 2021;13:4514. [PMID: 34572740 DOI: 10.3390/cancers13184514] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Voutsadakis IA. Biomarkers of Trifluridine-Tipiracil Efficacy. J Clin Med 2021;10:5568. [PMID: 34884270 DOI: 10.3390/jcm10235568] [Reference Citation Analysis]
5 Fernández Montes A, Carmona-Bayonas A, Jimenez-Fonseca P, Vázquez Rivera F, Martinez Lago N, Covela Rúa M, Cousillas Castiñeiras A, Gonzalez Villarroel P, De la Cámara Gómez J, Méndez JCM, Carriles Fernández C, Sanchez Cánovas M, Garcia García T. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Sci Rep 2021;11:14321. [PMID: 34253805 DOI: 10.1038/s41598-021-93732-5] [Reference Citation Analysis]
6 Mima K, Miyanari N, Kosumi K, Tajiri T, Kanemitsu K, Takematsu T, Inoue M, Mizumoto T, Kubota T, Baba H. The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients. Int J Clin Oncol 2021;26:903-12. [PMID: 33507434 DOI: 10.1007/s10147-021-01876-1] [Reference Citation Analysis]